Sponsor

Prevail Therapeutics Inc.

United States 645 Summer Street, 02210-2135, United States

About the sponsor

Prevail Therapeutics Inc. funds clinical research in Parkinson’s disease and fronto-temporal dementia, with a particular focus on forms linked to GBA1 and progranulin biology.

Parkinson’s disease
Parkinson’s disease with GBA1 mutation
Fronto-temporal dementia with progranulin mutations

The sponsor’s research in this area centers on neurological conditions associated with inherited molecular subtypes and disease-related protein regulation.

About Specializations

Prevail Therapeutics Inc. runs clinical trials in conditions such as Parkinson's disease, Gaucher's disease type I, Frontotemporal dementia, among others.

All trials

Ongoing trials

Clinical trials registered by this sponsor – none is enrolling right now.

Quick filters

3 clinical trials

Parkinson's disease

Not yet recruiting

Study on the Safety and Effects of LY3884961 for Patients with Parkinson's Disease and a GBA1 Mutation

InvestigationalNo placebo

Study on the Safety and Effects of LY3884961 for Patients with Parkinson's Disease and a GBA1 Mutation

InvestigationalNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Adeno-Associated Viral Vector Serotype 9 Expressing Codon-Optimized Human Gba Gene
Sponsor:Prevail Therapeutics Inc.